Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes

Angelo Antonini, Ashley Yegin, Cornelia Preda, Lars Bergmann, Werner Poewe

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Introduction: Intermittent oral delivery of levodopa is a major contributing factor for motor complications in Parkinson's disease (PD). Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) into the jejunum using a portable pump via percutaneous endoscopic gastrostomy (PEG) improves motor complications and quality of life (QoL). Objectives: To record long-term effectiveness of advanced PD patients undergoing LCIG infusion in routine care, by Unified Parkinson's Disease Rating Scale (UPDRS), Non-Motor Symptoms Scale (NMSS), PDQ-8 and EQ-5D questionnaires. Methods: Overall, 375 patients from 75 movement disorder centers in 18 countries were enrolled in this prospective non-interventional study. The 12-month interim outcomes of the first 172 included patients are presented here. Results: There were reductions of mean daily "Off" time from baseline (BL) (7.1±3.5h) and "On" time with dyskinesias (5.2±4.5h) at month 12 (M12) of -4.7±3.4 and -1.7±5.0h respectively (p

Original languageEnglish
Pages (from-to)231-235
Number of pages5
JournalParkinsonism and Related Disorders
Volume21
Issue number3
DOIs
Publication statusPublished - Mar 1 2015

Fingerprint

Parkinson Disease
Gels
Safety
Gastrostomy
Dyskinesias
Movement Disorders
Levodopa
Jejunum
Quality of Life
levodopa drug combination carbidopa
propylene diquat
Surveys and Questionnaires

Keywords

  • Advanced Parkinson's disease
  • Duodenal levodopa-carbidopa infusion
  • Motor symptoms
  • Non-motor symptoms
  • Quality of life
  • Routine patient care

ASJC Scopus subject areas

  • Geriatrics and Gerontology
  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes. / Antonini, Angelo; Yegin, Ashley; Preda, Cornelia; Bergmann, Lars; Poewe, Werner.

In: Parkinsonism and Related Disorders, Vol. 21, No. 3, 01.03.2015, p. 231-235.

Research output: Contribution to journalArticle

@article{37f82cd21b3a46abb069b21e19b423dd,
title = "Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes",
abstract = "Introduction: Intermittent oral delivery of levodopa is a major contributing factor for motor complications in Parkinson's disease (PD). Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) into the jejunum using a portable pump via percutaneous endoscopic gastrostomy (PEG) improves motor complications and quality of life (QoL). Objectives: To record long-term effectiveness of advanced PD patients undergoing LCIG infusion in routine care, by Unified Parkinson's Disease Rating Scale (UPDRS), Non-Motor Symptoms Scale (NMSS), PDQ-8 and EQ-5D questionnaires. Methods: Overall, 375 patients from 75 movement disorder centers in 18 countries were enrolled in this prospective non-interventional study. The 12-month interim outcomes of the first 172 included patients are presented here. Results: There were reductions of mean daily {"}Off{"} time from baseline (BL) (7.1±3.5h) and {"}On{"} time with dyskinesias (5.2±4.5h) at month 12 (M12) of -4.7±3.4 and -1.7±5.0h respectively (p",
keywords = "Advanced Parkinson's disease, Duodenal levodopa-carbidopa infusion, Motor symptoms, Non-motor symptoms, Quality of life, Routine patient care",
author = "Angelo Antonini and Ashley Yegin and Cornelia Preda and Lars Bergmann and Werner Poewe",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.parkreldis.2014.12.012",
language = "English",
volume = "21",
pages = "231--235",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes

AU - Antonini, Angelo

AU - Yegin, Ashley

AU - Preda, Cornelia

AU - Bergmann, Lars

AU - Poewe, Werner

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Introduction: Intermittent oral delivery of levodopa is a major contributing factor for motor complications in Parkinson's disease (PD). Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) into the jejunum using a portable pump via percutaneous endoscopic gastrostomy (PEG) improves motor complications and quality of life (QoL). Objectives: To record long-term effectiveness of advanced PD patients undergoing LCIG infusion in routine care, by Unified Parkinson's Disease Rating Scale (UPDRS), Non-Motor Symptoms Scale (NMSS), PDQ-8 and EQ-5D questionnaires. Methods: Overall, 375 patients from 75 movement disorder centers in 18 countries were enrolled in this prospective non-interventional study. The 12-month interim outcomes of the first 172 included patients are presented here. Results: There were reductions of mean daily "Off" time from baseline (BL) (7.1±3.5h) and "On" time with dyskinesias (5.2±4.5h) at month 12 (M12) of -4.7±3.4 and -1.7±5.0h respectively (p

AB - Introduction: Intermittent oral delivery of levodopa is a major contributing factor for motor complications in Parkinson's disease (PD). Continuous infusion of levodopa-carbidopa intestinal gel (LCIG) into the jejunum using a portable pump via percutaneous endoscopic gastrostomy (PEG) improves motor complications and quality of life (QoL). Objectives: To record long-term effectiveness of advanced PD patients undergoing LCIG infusion in routine care, by Unified Parkinson's Disease Rating Scale (UPDRS), Non-Motor Symptoms Scale (NMSS), PDQ-8 and EQ-5D questionnaires. Methods: Overall, 375 patients from 75 movement disorder centers in 18 countries were enrolled in this prospective non-interventional study. The 12-month interim outcomes of the first 172 included patients are presented here. Results: There were reductions of mean daily "Off" time from baseline (BL) (7.1±3.5h) and "On" time with dyskinesias (5.2±4.5h) at month 12 (M12) of -4.7±3.4 and -1.7±5.0h respectively (p

KW - Advanced Parkinson's disease

KW - Duodenal levodopa-carbidopa infusion

KW - Motor symptoms

KW - Non-motor symptoms

KW - Quality of life

KW - Routine patient care

UR - http://www.scopus.com/inward/record.url?scp=84923230653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923230653&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2014.12.012

DO - 10.1016/j.parkreldis.2014.12.012

M3 - Article

C2 - 25585993

AN - SCOPUS:84923230653

VL - 21

SP - 231

EP - 235

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

IS - 3

ER -